The Network aims to promote multi-disciplinary approaches to address challenging vaccine-related questions. This page contains a curated list of publications that highlight high-impact and collaborative approaches.
@article{White:2015:10.1016/j.vaccine.2015.09.099,
author = {White, MT and Verity, R and Churcher, TS and Ghani, AC},
doi = {10.1016/j.vaccine.2015.09.099},
journal = {Vaccine},
pages = {7544--7550},
title = {Vaccine approaches to malaria control and elimination: Insights from mathematical models},
url = {http://dx.doi.org/10.1016/j.vaccine.2015.09.099},
volume = {33},
year = {2015}
}
TY - JOUR
AB - A licensed malaria vaccine would provide a valuable new tool for malaria control and elimination efforts.Several candidate vaccines targeting different stages ofthe malaria parasite’s lifecycle are currently underdevelopment, with one candidate, RTS,S/AS01 for the prevention of Plasmodium falciparum infection,having recently completed Phase III trials. Predicting the public health impact of a candidate malariavaccine requires using clinical trial data to estimate the vaccine’s efficacy profile—the initial efficacyfollowing vaccination and the pattern of waning of efficacy over time. With an estimated vaccine efficacyprofile, the effects of vaccination on malaria transmission can be simulated with the aid of mathematicalmodels.Here, we provide an overview of methods for estimating the vaccine efficacy profiles of pre-erythrocyticvaccines and transmission-blocking vaccines from clinicaltrial data. In the case of RTS,S/AS01, model estimatesfrom Phase II clinical trial data indicate a bi-phasic exponential profile of efficacy against infection,with efficacy waning rapidly in the first 6 months after vaccination followed by a slower rate of waningover the next 4 years. Transmission-blocking vaccines have yet to be tested in large-scale Phase II orPhase III clinical trials so we review ongoing work investigating how a clinical trial might be designed toensure that vaccine efficacy can be estimated with sufficient statistical power. Finally, we demonstratehow parameters estimated from clinical trials can be used to predict the impact of vaccination campaignson malaria using a mathematical model of malaria transmission
AU - White,MT
AU - Verity,R
AU - Churcher,TS
AU - Ghani,AC
DO - 10.1016/j.vaccine.2015.09.099
EP - 7550
PY - 2015///
SN - 1873-2518
SP - 7544
TI - Vaccine approaches to malaria control and elimination: Insights from mathematical models
T2 - Vaccine
UR - http://dx.doi.org/10.1016/j.vaccine.2015.09.099
UR - http://hdl.handle.net/10044/1/30554
VL - 33
ER -